Main Article Content

Badruddeen Badruddeen


This review highlights the potential indications of Saxagliptin and its combinations including several analytical aspects. The selective, reversible dipeptidyl peptidase-4 inhibitor Saxagliptin and its active metabolite M2 are used to improve the glycaemic control in type 2 diabetic patients. Saxagliptin prevents the inactivation of the incretin hormones namely glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. This increases glucagon-like peptide-1 levels, stimulates insulin secretion and reduces the postprandial glucagon and glucose levels in the body. Saxagliptin therapy in patient with type 2 diabetes are prescribed as monotherapy or as add-on therapy to Metformin, Sulphonyl urea and Thiazolidine-diones, without significant change in body weight while exhibiting a low risk of hypoglycaemia. There is a significant enhancement in the HbA1C levels relative to continued use of existing monotherapy. Some potential indications of Saxagliptin include metabolic disorders, inflammatory disorders, hepatic disorders, neurological disorders and as well as cardiac disease..


Download data is not yet available.

Article Details

How to Cite
Badruddeen, B. (2020). SAXAGLIPTIN: A SYSTEMATIC REVIEW ON ITS PHARMACOLOGICAL POTENTIAL AND ANALYTICAL ASPECTS. Innovat International Journal Of Medical & Pharmaceutical Sciences, 5(5). Retrieved from
Review Article(s)


Ahren B. “DPP-4 inhibitors†Best Practice & Research Clinical Endocrinology & Etabolism, 2007, 21(4): 517-533. 2. Ali S, Fonseca V. “Saxagliptin overview: special focus on safety and adverse effects. Expert opinion on drug safety†2013, 12(1): 103-109. 3. Anderson R, Hayes J, et al. “Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes†Expert Opinion on Drug Metabolism & Toxicology, 2016, 12(4): 467-473.

Augeri DJ, Robl JA, et al. “Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes†J Med Chem, 2005, 48: 5025–5037.

Barnett AH, Charbonnel B, et al. “Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin†Curr Med Res Opin, 2012,28(4):513-23.

Barnett AH, Charbonnel B,et al. “Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy†Diabetologia,, 2011,54:S108-9. 7. Batta N, Pilli NR, et al. “A Rapid and Sensitive LC-MS/MS Assay for the Determination of Saxagliptin and its Active Metabolite 5-Hydroxy Saxagliptin in Human Plasma and its application to a pharmacokinetic study†Drug research, 2015, 65(03):133-408. Boulton David W, “Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor†Springer International Publishing Switzerland, 2016, 56(1): 11–24.

Boulton DW, Geraldes M, et al. “Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects†Presented at: 67th Scientific Sessions of the American Diabetes Association: Chicago, 2007, 606P. 10. Boulton DW. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clinical pharmacokinetics. 2017 Jan;56(1):11-24. 11. Caglar S, Alp AR. et al. “A validated high performance liquid chromatography method for the determination of saxagliptin and metformin in bulk, a stability indicating study†J Anal Bioanal Tech S, 2014, 12: 2.

Cole PSN, Bolós J, et al. “Saxagliptin†Drugs of the Future, 2008, 33(7):577-86. 13. Coskun ZM, et al. “ER Stress Amelioration by Saxagliptin Protects the Liver Against Fructose-induced Insulin Resistance†Archives of Medical Research, 2020. 14. Deacon CF, Holst JJ, et al. “Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety†Expert opinion on pharmacotherapy, 2013, 14(15): 2047-2058.

DeFronzo,RA, Hissa MN, et al. “The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone†Diabetes Care, 2009, 32(9):1649–55.

Dore DD, Seeger JD, et al. “Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide†Curr Med Res Opin, 2009, 25(4):1019-27.

Drucker DJ, “Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes – Preclinical biology and mechanisms of action†2007, Diabetes Care, 30: 1335-43. 18. Drucker DJ, Nauck MA, et al. “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes†The Lancet, 2006, 368(9548): 1696-1705.

Engel SS, Williams-Herman DE, et al. “Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis†Int J Clin Pract, 2010, 64(7):984-90. 20. Gao JW, Yuan YM., et al. “Development of a rapid UPLCâ€MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study†Biomedical Chromatography, 2012, 26(12): 1482-1487.

Goke B, Gallwitz B, et al. “Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial†Int J Clin Pract, 2010, 64(12):1619-31.

Goke B, Gallwitz B, et al. “Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): long-term safety and efficacy†Diabetes, 2011,60:A305 23. Helal MG, Megahed NA, et al. “Saxagliptin mitigates airway inflammation in a mouse model of acute asthma via modulation of NF-kB and TLR4†Life sciences, 2019, 239: 117017. 24. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgraduate medicine. 2010 May 1;122(3):71-80. 25. Jadzinsky M, Pfutzner A, et al. “Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial†Diabetes Obes Metab, 2009, 11(6):611-22. 26. Kagal UA, Angadi NB, et al. “Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in maleWistar rats: an experimental study†International Journal of Applied and Basic Medical Research, 2017, 7(1):26. 27. Koyani CN, Kolesnik E, et al. “Maechler H. Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure†Biochemical pharmacology, 2017, 145:64-80. 28. Langley AK, Suffoletta, TJ, et al. “Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus†Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007, 27(8): 1163-1180. 29. Leibowitz G, Cahn A, et al. “Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVORâ€TIMI 53 study†Diabetes, Obesity and Metabolism, 2015, 17(5): 487-494. 30. Men P, Li XT, et al. “Efficacy and safety of saxagliptin in patients with type 2 diabetes†a systematic review and meta-analysis. PloS One, 2018,13(5):

Monami M, Dicembrini I, et al. “Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials†Curr Med Res Opin, 2011,27(Suppl 3):57-64. 32. Nassar NN, Al-Shorbagy MY, et al. “Saxagliptin: a novel antiparkinsonian approach†Neuropharmacology, 2015, 89:308-17. 33. Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. American Journal of Health-System Pharmacy. 2010 Sep 15;67(18):1515-25.

Patel CG, Li L, et al. “No effect of saxagliptin on QTc interval in healthy subjects†Presented at: American Diabetes Association 69th Scientific Sessions: New Orleans, LA, 2009. 35. Prasad PBN, Satyanaryana K, et al. “Development and Validation of a Method for Simultaneous Determination of Metformin and Saxagliptin in a Formulation by RP-HPLC†American Journal of Analytical Chemistry, 2015 6(11): 841.

Ranjan D, Sharma A, et al. “Saxagliptin and Dapagliflozin for type 2 Diabetes mellitus†A Review. International Journal of Drug Regulatory Affairs, 2018,6(3): 24-30.

Rosenstock J, Aguilar-Salinas C, et al. “Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes†Curr Med Res Opin, 2009, 25(10):2401.

Rosenstock J, Gross JL, et al. “Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes†Diabetes, 2011,60:A298. 39. Rosenstock J, Sankoh S, List JF. Glucoseâ€lowering activity of the dipeptidyl peptidaseâ€4 inhibitor saxagliptin in drugâ€naive patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2008 May;10(5):376-86. 40. Savage SA, Jones GS, et al. “Preparation of saxagliptin, a novel DPP-IV inhibitor†Organic Process Research & Development, 2009, 13(6): 1169-1176 41. Srividya S, Swetha E, et al. “Development and validation of a high performance thin layer chromatographic method for quantitative analysis of saxagliptin†American Journal of Analytical Chemistry, 2015, 6(10): 797.

Tekkeli SE, Kızıltaş MV, et al.“An HPLC method for the determination of saxagliptin in human plasma with fluorescence detection†Journal: Journal of Advances in Chemistry, 2013, 5(3): 43. Teleanu DM, Chircov C, et al. “Neuronanomedicine: An up-to-date overview†Pharmaceutics, 2019, 11(3): 101. 44. Tella SH, Rendell MS. DPP-4 inhibitors: focus on safety. Expert opinion on drug safety. 2015 Jan 2;14(1):127-40. 45. Wang A, Dorso C, et al. “Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor†BMC pharmacology, 2012, 12(1):2.

Yazbeck R, Howarth GS, et al. “Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease†Trends Pharmacol Sci, 2009, 30(11):600-7.